Genetics Generation Advancement Corp. (TPEX:4160)
Taiwan · Delayed Price · Currency is TWD 44.85
+0.55 (1.24%)
Apr 1, 2026, 1:30 PM CST
TPEX:4160 Revenue
In the year 2025, Genetics Generation Advancement had annual revenue of 603.11M TWD, down -8.88%. Genetics Generation Advancement had revenue of 169.20M in the quarter ending December 31, 2025, with 9.01% growth.
Revenue
603.11M
Revenue Growth
-8.88%
P/S Ratio
1.98
Revenue / Employee
5.80M
Employees
104
Market Cap
1.20B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 603.11M | -58.74M | -8.88% |
| Dec 31, 2024 | 661.86M | 69.36M | 11.71% |
| Dec 31, 2023 | 592.50M | 44.69M | 8.16% |
| Dec 31, 2022 | 547.81M | 28.30M | 5.45% |
| Dec 31, 2021 | 519.51M | 76.38M | 17.24% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Lotus Pharmaceutical | 20.51B |
| Bora Pharmaceuticals | 19.01B |
| PharmaEssentia | 15.63B |
| AViTA | 936.39M |
| Excelsior Biopharma | 898.26M |
| DV Biomed | 712.61M |
| Meribank Biotech | 486.52M |
| Mediera | 229.85M |